Both HDRA and PDX models derived from the BRAF-mutated melanoma showed significant response to BRAF and MEK inhibitors, and those derived from the NRAS-mutated melanoma showed a significant response only to the MEK inhibitor pimasertib. This evidence concerns the gene BRAF and melanoma.